Virtual Screening for the Discovery of Active Principles from Natural Products
暂无分享,去创建一个
[1] Claudio N. Cavasotto,et al. Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.
[2] Jürgen Bajorath,et al. Molecular Similarity Concepts for Informatics Applications. , 2017, Methods in molecular biology.
[3] Jaap Heringa,et al. SEQATOMS: a web tool for identifying missing regions in PDB in sequence context , 2008, Nucleic Acids Res..
[4] Gisbert Schneider,et al. Automating drug discovery , 2017, Nature Reviews Drug Discovery.
[5] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[6] R. Bauer,et al. Polyacetylenes from Notopterygium incisum–New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma , 2013, PloS one.
[7] J. Kirchmair,et al. Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..
[8] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[9] J. Gasteiger,et al. Chemoinformatics: A Textbook , 2003 .
[10] J. Irwin,et al. Lead discovery using molecular docking. , 2002, Current opinion in chemical biology.
[11] J. Bajorath,et al. Follow up: Advancing the activity cliff concept, part II , 2014, F1000Research.
[12] Yuan-Ping Pang,et al. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies , 1994, J. Comput. Aided Mol. Des..
[13] Jürgen Bajorath,et al. Selected Concepts and Investigations in Compound Classification, Molecular Descriptor Analysis, and Virtual Screening , 2001, J. Chem. Inf. Comput. Sci..
[14] R. Bauer,et al. Drugs from nature targeting inflammation (DNTI): a successful Austrian interdisciplinary network project , 2016, Monatshefte für Chemie - Chemical Monthly.
[15] Alexander D. MacKerell,et al. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. , 2011, Current computer-aided drug design.
[16] Kathryn M Hart,et al. Discovery of multiple hidden allosteric sites by combining Markov state models and experiments , 2015, Proceedings of the National Academy of Sciences.
[17] Gerhard Wolber,et al. Arginase Structure and Inhibition: Catalytic Site Plasticity Reveals New Modulation Possibilities , 2017, Scientific Reports.
[18] Stefano Moro,et al. Bridging Molecular Docking to Membrane Molecular Dynamics To Investigate GPCR-Ligand Recognition: The Human A2A Adenosine Receptor as a Key Study , 2014, J. Chem. Inf. Model..
[19] Yun He,et al. Learning from the Data: Mining of Large High-Throughput Screening Databases , 2006, J. Chem. Inf. Model..
[20] T. Langer,et al. Strategies for efficient lead structure discovery from natural products. , 2006, Current medicinal chemistry.
[21] Adam Nelson,et al. Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries , 2008, Natural product reports.
[22] Christoph Steinbeck,et al. Natural product-likeness score revisited: an open-source, open-data implementation , 2012, BMC Bioinformatics.
[23] Björn Windshügel,et al. LEADS-PEP: A Benchmark Data Set for Assessment of Peptide Docking Performance , 2016, J. Chem. Inf. Model..
[24] F. Brown. Chapter 35 – Chemoinformatics: What is it and How does it Impact Drug Discovery. , 1998 .
[25] Roberto Todeschini,et al. Towards Global QSAR Model Building for Acute Toxicity: Munro Database Case Study , 2014, International journal of molecular sciences.
[26] N. Nikolova,et al. International Union of Pure and Applied Chemistry, LUMO energy ± The Lowest Unoccupied Molecular Orbital (LUMO) , 2022 .
[27] J. Rollinger,et al. Natural products modulating the hERG channel: heartaches and hope† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7np00014f , 2017, Natural product reports.
[28] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[29] Haruki Nakamura,et al. Remediation of the protein data bank archive , 2007, Nucleic Acids Res..
[30] N. Cohen,et al. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. , 2007, Chemical biology & drug design.
[31] Sichao Wang,et al. Recent developments in computational prediction of HERG blockage. , 2013, Current topics in medicinal chemistry.
[32] Alexander S. Hauser,et al. GPCRdb in 2018: adding GPCR structure models and ligands , 2017, Nucleic Acids Res..
[33] Thierry Langer,et al. Combining Ethnopharmacology and Virtual Screening for Lead Structure Discovery: COX-Inhibitors as Application Example , 2004, J. Chem. Inf. Model..
[34] Jens Meiler,et al. Autocorrelation descriptor improvements for QSAR: 2DA_Sign and 3DA_Sign , 2016, Journal of Computer-Aided Molecular Design.
[35] Igor V Tetko,et al. The WWW as a tool to obtain molecular parameters. , 2003, Mini reviews in medicinal chemistry.
[36] Kangyu Chen,et al. Stepwise high-throughput virtual screening of Rho kinase inhibitors from natural product library and potential therapeutics for pulmonary hypertension , 2015, Pharmaceutical biology.
[37] Ricardo Macarron,et al. Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.
[38] Dan Li,et al. Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. , 2016, Physical chemistry chemical physics : PCCP.
[39] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[40] Christina E. Mair,et al. hERG Channel Blocking Ipecac Alkaloids Identified by Combined In Silico – In Vitro Screening , 2016, Planta Medica.
[41] Aurélien Grosdidier,et al. SwissDock, a protein-small molecule docking web service based on EADock DSS , 2011, Nucleic Acids Res..
[42] Tingjun Hou,et al. Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility , 2014, J. Chem. Inf. Model..
[43] Strohl,et al. The role of natural products in a modern drug discovery program. , 2000, Drug discovery today.
[44] Daisuke Kihara,et al. Three-Dimensional Compound Comparison Methods and Their Application in Drug Discovery , 2015, Molecules.
[45] J. Tuszynski,et al. Software for molecular docking: a review , 2017, Biophysical Reviews.
[46] Gisbert Schneider,et al. Deep Learning in Drug Discovery , 2016, Molecular informatics.
[47] Thierry Langer,et al. Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..
[48] U. Holzgrabe,et al. Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor* , 2016, The Journal of Biological Chemistry.
[49] Sean Ekins,et al. The importance of discerning shape in molecular pharmacology. , 2009, Trends in pharmacological sciences.
[50] Andreas Bender,et al. Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..
[51] M. Zehl,et al. Catechol alkenyls from Semecarpus anacardium: acetylcholinesterase inhibition and binding mode predictions. , 2012, Journal of ethnopharmacology.
[52] David Lagorce,et al. FAF‐Drugs4: free ADME‐tox filtering computations for chemical biology and early stages drug discovery , 2017, Bioinform..
[53] Rajarshi Guha,et al. Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..
[54] Matthias Buck,et al. The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity , 2011 .
[55] Pedro J. Ballester,et al. Performance of machine-learning scoring functions in structure-based virtual screening , 2017, Scientific Reports.
[56] Thierry Langer,et al. Common Hits Approach: Combining Pharmacophore Modeling and Molecular Dynamics Simulations , 2017, J. Chem. Inf. Model..
[57] Henry Ho,et al. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models , 2015, J. Chem. Inf. Model..
[58] Stefan Wetzel,et al. Cheminformatic Analysis of Natural Products and their Chemical Space , 2007 .
[59] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[60] S. Free,et al. A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.
[61] Sjors H. W. Scheres,et al. Unravelling biological macromolecules with cryo-electron microscopy , 2016, Nature.
[62] M. Karelson,et al. Quantum-Chemical Descriptors in QSAR/QSPR Studies. , 1996, Chemical reviews.
[63] G. Degliesposti,et al. Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening , 2009, Chemical biology & drug design.
[64] Charlotte M. Deane,et al. Freely Available Conformer Generation Methods: How Good Are They? , 2012, J. Chem. Inf. Model..
[65] C. Ung,et al. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? , 2003, Natural product reports.
[66] Xiaoqin Zou,et al. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. , 2010, Physical chemistry chemical physics : PCCP.
[67] Haruki Nakamura,et al. Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.
[68] Yoshihiro Yamanishi,et al. Benchmarking a Wide Range of Chemical Descriptors for Drug‐Target Interaction Prediction Using a Chemogenomic Approach , 2014, Molecular informatics.
[69] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[70] Petra Schneider,et al. Revealing the macromolecular targets of complex natural products. , 2014, Nature chemistry.
[71] Thierry Langer,et al. High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening , 2007, J. Comput. Aided Mol. Des..
[72] Theodora M. Steindl,et al. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. , 2008, Journal of medicinal chemistry.
[73] Daniela Schuster,et al. Predicting Cyclooxygenase Inhibition by Three‐Dimensional Pharmacophoric Profiling. Part I: Model Generation, Validation and Applicability in Ethnopharmacology , 2010, Molecular informatics.
[74] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[75] Lirong Chen,et al. Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology , 2013, PloS one.
[76] Károly Héberger,et al. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? , 2015, Journal of Cheminformatics.
[77] Tian Zhu,et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.
[78] Igor I. Baskin,et al. Machine Learning Methods for Property Prediction in Chemoinformatics: Quo Vadis? , 2012, J. Chem. Inf. Model..
[79] Gaozhi Chen,et al. Determination of the binding mode for anti-inflammatory natural product xanthohumol with myeloid differentiation protein 2 , 2016, Drug design, development and therapy.
[80] Steffen Hering,et al. Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening , 2015, Future medicinal chemistry.
[81] G. Wolber,et al. Identification of PPARγ Agonists from Natural Sources Using Different In Silico Approaches , 2014, Planta Medica.
[82] Simona Distinto,et al. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..
[83] Arthur Dalby,et al. Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited , 1992, J. Chem. Inf. Comput. Sci..
[84] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[85] Cícero Nogueira dos Santos,et al. Boosting Docking-Based Virtual Screening with Deep Learning , 2016, J. Chem. Inf. Model..
[86] Russ B Altman,et al. Machine learning in chemoinformatics and drug discovery. , 2018, Drug discovery today.
[87] R. M. Muir,et al. Correlation of Biological Activity of Phenoxyacetic Acids with Hammett Substituent Constants and Partition Coefficients , 1962, Nature.
[88] Robert P. Sheridan. Alternative Global Goodness Metrics and Sensitivity Analysis: Heuristics to Check the Robustness of Conclusions from Studies Comparing Virtual Screening Methods , 2008, J. Chem. Inf. Model..
[89] Daniela Schuster,et al. Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum , 2011, Bioorganic & medicinal chemistry.
[90] C. Wermuth,et al. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .
[91] Antonio Lavecchia,et al. Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.
[92] Jung-Hsin Lin,et al. idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach , 2012, Nucleic Acids Res..
[93] T Langer,et al. Integrated in silico tools for exploiting the natural products' bioactivity. , 2006, Planta medica.
[94] Edward W. Lowe,et al. Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.
[95] György M. Keserü,et al. The Impact of Molecular Dynamics Sampling on the Performance of Virtual Screening against GPCRs , 2013, J. Chem. Inf. Model..
[96] David E. Gloriam,et al. Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.
[97] A. Harvey,et al. The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.
[98] Ajay N. Jain,et al. Recommendations for evaluation of computational methods , 2008, J. Comput. Aided Mol. Des..
[99] H. Kokubo,et al. Exploring the Stability of Ligand Binding Modes to Proteins by Molecular Dynamics Simulations: A Cross-docking Study , 2017, J. Chem. Inf. Model..
[100] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .
[101] Jonathan B Baell,et al. Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS). , 2016, Journal of natural products.
[102] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[103] Gisbert Schneider,et al. A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds. , 2017, Angewandte Chemie.
[104] Christopher I. Bayly,et al. Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..
[105] Francisco Corzana,et al. Unveiling (−)‐Englerin A as a Modulator of L‐Type Calcium Channels , 2016, Angewandte Chemie.
[106] Daniela Schuster,et al. Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools , 2014, J. Chem. Inf. Model..
[107] T Langer,et al. Lead optimization Pharmacophore definition and 3 D searches , 2005 .
[108] Diane Joseph-McCarthy,et al. Ensemble-Based Docking Using Biased Molecular Dynamics , 2014, J. Chem. Inf. Model..
[109] Jiye Shi,et al. Like-Charge Guanidinium Pairing between Ligand and Receptor: An Unusual Interaction for Drug Discovery and Design? , 2015, The journal of physical chemistry. B.
[110] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[111] Stefano Alcaro,et al. A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins , 2015, J. Chem. Inf. Model..
[112] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[113] Clemencia Pinilla,et al. A Similarity‐based Data‐fusion Approach to the Visual Characterization and Comparison of Compound Databases , 2007, Chemical biology & drug design.
[114] Olivier Sperandio,et al. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.
[115] Johann Gasteiger,et al. Chemoinformatics: Achievements and Challenges, a Personal View , 2016, Molecules.
[116] Spandana Makeneni,et al. Applying Pose Clustering and MD Simulations To Eliminate False Positives in Molecular Docking , 2018, J. Chem. Inf. Model..
[117] Jung-Keun Suh,et al. ulti-conformation dynamic pharmacophore modeling of the eroxisome proliferator-activated receptor for the discovery of ovel agonists , 2013 .
[118] Dik-Lung Ma,et al. Molecular docking for virtual screening of natural product databases , 2011 .
[119] Luca Mollica,et al. Kinetics of protein-ligand unbinding via smoothed potential molecular dynamics simulations , 2015, Scientific Reports.
[120] Jonathan W. Essex,et al. A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..
[121] Yu-chian Chen. Beware of docking! , 2015, Trends in pharmacological sciences.
[122] A. Cavalli,et al. Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.
[123] D. Goodsell,et al. Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock , 2002, Proteins.
[124] T. Langer,et al. Accessing biological actions of Ganoderma secondary metabolites by in silico profiling. , 2015, Phytochemistry.
[125] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[126] Chun Wu,et al. Binding of Telomestatin to a Telomeric G-Quadruplex DNA Probed by All-Atom Molecular Dynamics Simulations with Explicit Solvent , 2016, J. Chem. Inf. Model..
[127] Matthias Rarey,et al. Benchmarking Commercial Conformer Ensemble Generators , 2017, J. Chem. Inf. Model..
[128] Ulrich Rester,et al. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. , 2008, Current opinion in drug discovery & development.
[129] Thierry Langer,et al. Discovering COX-inhibiting constituents of Morus root bark: activity-guided versus computer-aided methods. , 2005, Planta medica.
[130] William H. Gerwick,et al. Retrospective analysis of natural products provides insights for future discovery trends , 2017, Proceedings of the National Academy of Sciences.
[131] Guan Wang,et al. Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: a case study of PDE5 and its inhibitors. , 2014, Journal of medicinal chemistry.
[132] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[133] Thomas Seidel,et al. Strategies for 3D pharmacophore-based virtual screening. , 2010, Drug discovery today. Technologies.
[134] Violeta I. Pérez-Nueno,et al. Highly SpecIfic and Sensitive Pharmacophore Model for Identifying CXCR4 Antagonists. Comparison with Docking and Shape-Matching Virtual Screening Performance , 2013, J. Chem. Inf. Model..
[135] Thierry Langer,et al. In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.
[136] David DeCaprio,et al. Cheminformatics approaches to analyze diversity in compound screening libraries. , 2010, Current opinion in chemical biology.
[137] B. Shoichet,et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.
[138] Daniela Schuster,et al. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation , 2011, Bioorganic & medicinal chemistry.
[139] Alexandru T. Balaban. Neural Networks in QSAR and Drug Design. Edited by J. Devillers. Volume 2 in the Series: Principles of QSAR and Drug Design. Academic Press: San Diego, 1996, 284 pp. ISBN 0-12-213815-5 , 1997, J. Chem. Inf. Comput. Sci..
[140] Noel M. O'Boyle. Towards a Universal SMILES representation - A standard method to generate canonical SMILES based on the InChI , 2012, Journal of Cheminformatics.
[141] Weiliang Zhu,et al. Molecular docking for drug discovery and development: a widely used approach but far from perfect. , 2016, Future medicinal chemistry.
[142] G. Hessler,et al. The scaffold hopping potential of pharmacophores. , 2010, Drug discovery today. Technologies.
[143] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[144] Artem Cherkasov,et al. Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action , 2017, J. Chem. Inf. Model..
[145] Christophe Chipot,et al. Standard binding free energies from computer simulations: What is the best strategy? , 2013, Journal of chemical theory and computation.
[146] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[147] G. Bifulco,et al. New steroids with a rearranged skeleton as (h)P300 inhibitors from the sponge Theonella swinhoei. , 2014, Organic letters.
[148] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[149] Shuichi Hirono,et al. Comparison of Consensus Scoring Strategies for Evaluating Computational Models of Protein-Ligand Complexes , 2006, J. Chem. Inf. Model..
[150] Stewart A. Adcock,et al. Molecular dynamics: survey of methods for simulating the activity of proteins. , 2006, Chemical reviews.
[151] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[152] Klaus R. Liedl,et al. One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..
[153] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[154] Lorenz C. Blum,et al. Chemical space as a source for new drugs , 2010 .
[155] Y. Sugita,et al. Reaching new levels of realism in modeling biological macromolecules in cellular environments. , 2013, Journal of molecular graphics & modelling.
[156] Thierry Langer,et al. In Silico Workflow for the Discovery of Natural Products Activating the G Protein-Coupled Bile Acid Receptor 1 , 2018, Front. Chem..
[157] J. Rollinger,et al. Computer-Guided Approach to Access the Anti-influenza Activity of Licorice Constituents , 2013, Journal of natural products.
[158] Dieter Lang,et al. Predicting drug metabolism: experiment and/or computation? , 2015, Nature Reviews Drug Discovery.
[159] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[160] John H. Van Drie,et al. History of 3D pharmacophore searching: commercial, academic and open-source tools. , 2010, Drug discovery today. Technologies.
[161] Daniela Schuster,et al. Ligand-Based Pharmacophore Modeling and Virtual Screening for the Discovery of Novel 17β-Hydroxysteroid Dehydrogenase 2 Inhibitors , 2014, Journal of medicinal chemistry.
[162] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[163] A. Anderson. The process of structure-based drug design. , 2003, Chemistry & biology.
[164] A. Ghose,et al. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.
[165] J. Gostner,et al. A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature , 2017, Scientific Reports.
[166] P. Hawkins,et al. Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.
[167] Danishuddin,et al. Descriptors and their selection methods in QSAR analysis: paradigm for drug design. , 2016, Drug discovery today.
[168] Simona Distinto,et al. How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..
[169] Sorel Muresan,et al. ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.
[170] K. Luthman,et al. Selective Pharmacophore Models of Dopamine D1 and D2 Full Agonists Based on Extended Pharmacophore Features , 2010, ChemMedChem.
[171] J. Bajorath,et al. Advancing the activity cliff concept , 2013 .
[172] D. Hoekman. Exploring QSAR Fundamentals and Applications in Chemistry and Biology, Volume 1. Hydrophobic, Electronic and Steric Constants, Volume 2 J. Am. Chem. Soc. 1995, 117, 9782 , 1996 .
[173] Judith M. Rollinger,et al. Accessing target information by virtual parallel screening—The impact on natural product research , 2009 .